The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries

PharmacoEconomics

Volumn 31, Issue 11, 2013, Pages 1063-1082

  Babar, Zaheer Ud Din ^a   Lessing, Charon ^a   Mace, Cécile ^b   Bissell, Karen ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; SALBUTAMOL; SALBUTAMOL SULFATE;

AFGHANISTAN; ARTICLE; ASTHMA; BANGLADESH; BENIN; BRAZIL; BURKINA FASO; BURUNDI; CAMBODIA; CAMEROON; CHILE; CHINA; CONGO; CROSS-SECTIONAL STUDY; DJIBOUTI; DRUG COST; ECUADOR; EGYPT; EL SALVADOR; ETHIOPIA; GOVERNMENT; GUINEA; HAITI; HEALTH CARE ACCESS; HEALTH CARE SURVEY; HONDURAS; HUMAN; INCOME; INDIA; INDONESIA; INHALER; INTERNATIONAL REFERENCE PRICE; IRAN; JORDAN; KENYA; MADAGASCAR; MALAWI; MALAYSIA; MALI; MAURITANIA; MEXICO; MIDDLE INCOME COUNTRY; MOROCCO; MOZAMBIQUE; MYANMAR; NEPAL; NIGERIA; ORGANIZATION AND MANAGEMENT; PAKISTAN; PERU; PHARMACY; PHILIPPINES; PRIORITY JOURNAL; PUBLIC HOSPITAL; REIMBURSEMENT; SOCIAL INSURANCE; SOCIAL STATUS; SOUTH AFRICA; SRI LANKA; SUDAN; SYRIAN ARAB REPUBLIC; TANZANIA; THAILAND; TOGO; TUVALU; UGANDA; VANUATU; VIET NAM; YEMEN; ZAMBIA; ZIMBABWE;

ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BUDESONIDE; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DEVELOPING COUNTRIES; DRUG COSTS; GLUCOCORTICOIDS; HEALTH SERVICES ACCESSIBILITY; HUMANS; REIMBURSEMENT MECHANISMS;

EID: 84890365404     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0095-9     Document Type: Article

References (35)

1. World Health Organization. WHO Model List of Essential Medicines. Geneva: World Health Organization; 2011. http://www.who.int/medicines/publications/ essentialmedicines/en/. Accessed 17 Sep 2013.
2. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373:240-9.
3. Quick J, Rankin J, Laing R, O'Connor R, Hogerzeil H, editors. Managing drug supply. 2nd ed. West Hartford: Kumarian Press; 1997.
4. Creese A, Gasman N, Mariko M. The World Medicines Situation. Geneva: World Health Organization; 2004. http://apps.who.int/medicinedocs/en/d/Js6160e/. Accessed 15 Aug 2013.
5. Management Sciences for Health. International drug price indicator guide. Boston: Management Sciences for Health; 2005. http://erc.msh.org/mainpage.cfm? file=1.0.htm&module=Dmp&language=English. Accessed 1 Feb 2011.
6. Organization for Economic Co-operation and Development (OECD). Drug spending in OECD countries up by nearly a third since 1998, according to new OECD data (2005). http://www.oecd.org/document/25/20,2340,en-2649-37407- 34967193-34967191-34967191-34967191-34937407,34967100.html. Accessed 13 Aug 2013.
7. Hogerzeil H. MDG target 8E gap analysis. Geneva: World Health Organization; 2008.
8. Millennium Development Group Gap Task Force. Delivering on the global partnership for achieving the millennium development goals: MDG Gap Task Force Report. New York: United Nations; 2008.
9. World Health Organization. The World Medicines Situation 2011. WHO/EMP/MIE/2011.2.1. Geneva: World Health Organization; 2011.
10. Mendis S, Fukino K, Cameron A, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007;85:279-88.
11. World Health Organization (WHO) and Health Action International (HAI). Medicine prices - a new approach to measurement, Geneva (2003). http://whqlibdoc.who.int/hq/2003/WHO-EDM-PAR-2003.2002.pdf.
12. World Health Organization. Chronic respiratory diseases. Geneva: World Health Organization. http://www.who.int/gard/publications/chronic-respiratory- diseases.pdf. Accessed 17 Sep 2013.
13. Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry crosssectional surveys. Lancet. 2006;368:733-43.
14. Lai CKW, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64:476-83.
15. Chinn S, Jarvis D, Burney P, et al. Increase in diagnosed asthma but not in symptoms in the European Community Respiratory Health Survey. Thorax. 2004;59:646-51.
16. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114:40-7.
17. Lalloo UG, McIvor RA. Management of chronic asthma in adults in diverse regions of the world. Int J Tuberc Lung Dis. 2006;10:474-83.
18. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.
19. Jonsson B. Measuring the economic burden in asthma. In: Weiss K, Buist AS, Sulivan SD, editors. Asthma's Impact on Society: the social and economic burden. New York: Marcel Dekker; 1999. pp. 251-267.
20. Lai CKW, Kim Y-Y, Kuo S-H, et al. Cost of asthma in the Asia Pacific region. Eur Resp Rev. 2006;15:10-6.
21. Ait-Khaled N, Anderson H, Asher M, Babar Z, Bissell K, et al. (2011) Global Asthma Report. Paris: International Union against Tuberculosis and Lung Disease and The International Study of Asthma and Allergies in Childhood. http://www.globalasthmareport.org/. Accessed 15 Aug 2013.
22. Kotwani A. Availability, price and affordability of asthma medicines in five Indian states. Int J Tuberc Lung Dis. 2009;13:574-9.
23. Mace C, Bissell K, Billo N. Access to essential asthma medicines: the response of the Asthma Drug Facility. World Health Organization Essential Medicines Monitor: 2011;5.
24. The World Bank. GNI per capita, Atlas method (current US$) [online]. http://data.worldbank.org/indicator/NY.GNP.PCAP.CD. Accessed 17 Sep 2013.
25. Liamputtong PED. Qualitative research methods. Melbourne: Oxford University Press; 2005.
26. McFadyen JE. International drug price indicator guide. Boston: Management Sciences for Health; 2010. pp E3 to P2-18.
27. WHO/HAI. Measuring medicine prices, availability, affordability and price components. Geneva: World Health Organization/Health Action International; 2008.
28. Babar ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese A. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007;4:e82.
29. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and affordability: an international comparison of chronic disease medicines. World Health Organization and Health Action International; 2006. http://www.who.int/ medicines/publications/PriceAvailAfordability.pdf. Accessed 10 Aug 2013.
30. Aït-Khaled N, Enarson DA, Chiang C-Y, Marks G, Bissell K. Management of asthma: a guide to the essentials of good clinical practice. 3rd ed. Paris: International Union Against Tuberculosis and Lung Disease; 2008. http://www.theunion.org/index.php/en/resources/technical-publications/. Accessed 17 Sep 2013.
31. Global Initiative for Asthma. Pocket guide for asthma prevention and management. 2011. http://www.ginasthma.org/local/uploads/files/GINA-Pocket- April20-1.pdf. Accessed 17 Sep 2013.
32. World Health Organization. The World Medicines Situation. Geneva: World Health Organisation; 2004.
33. Keith J, McDonald GPM. Transition to CFC-free metered dose inhalers - into the new millennium. Int J Pharm. 2000;201:89-107.
34. Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, et al. Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med. 2010;7:1-8.
35. The World Bank. Health expenditures per capita. http://data.worldbank. org/indicator/SH.XPD.PCAP. Accessed 17 Sep 2013.